Principles of medical and oncological management of giant masses of the mediastinum: a narrative review

Giant mediastinal tumors are represented by well-defined histological variants originating from different structures and compartments while their clinical presentation may be similar and characterized by the same set of symptoms, the well-known mediastinal syndrome (MS). In 80% of cases the MS is ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mediastinum (Hong Kong, China) China), 2022, Vol.6, p.35-35
Hauptverfasser: Conci, Nicole, Grilli, Giada, Dall'Olio, Filippo G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 35
container_issue
container_start_page 35
container_title Mediastinum (Hong Kong, China)
container_volume 6
creator Conci, Nicole
Grilli, Giada
Dall'Olio, Filippo G
description Giant mediastinal tumors are represented by well-defined histological variants originating from different structures and compartments while their clinical presentation may be similar and characterized by the same set of symptoms, the well-known mediastinal syndrome (MS). In 80% of cases the MS is caused by malignant neoplasms, such as lung tumors, in 10-18% of cases by hematological neoplasms and in 2-3% by benign causes. In this review we investigated the medical treatment of main giant mediastinal tumors, focusing our interest on the objective response rate (ORR), as it represents the most suitable parameter to predict the volumetric reduction of the neoplasm and, consequently, the regression of their most severe complication, the MS. We will also cover the supportive and symptomatic treatment of MS. We performed a deep analysis of the recent international literature published on PUBMED, UpToDate and Medline. The literature search was undertaken from origin until November 30th, 2021, and we only considered publications in English. Considering the variety of pathologies that can occur in the mediastinum, a rapid histological characterization of the neoplasm is mandatory. In fact, the treatment of these neoplasms includes different approaches, sometimes used in combination, which include chemotherapy, radiotherapy, and surgery. The vena cava syndrome (VCS), due to its high mortality, is considered an oncological emergency and, therefore, requires effective treatments carried out urgently, evaluated in multidisciplinary meeting. The treatment of MS includes both antiblastic treatments and therapies directed to the symptoms. Among the former, chemotherapy, target therapy, radiation and surgery may be used, according to the etiology of MS. Among the latters, supportive therapies, interventional radiology procedures such as stenting may help manage this syndrome, despite the prognosis is poor in most cases and linked to the histology of the tumor, which therefore represents the most important prognostic factor.
doi_str_mv 10.21037/med-21-54
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9792870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2759956691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2234-33411fb8f26fcdedb0cbfac36c021eca6af7ab46afbf514468b3551cd44816703</originalsourceid><addsrcrecordid>eNpVkU1LxDAQhoMoKurFHyA9ilDNd1sPgix-gaAHPYdpmtRIm6xJd8V_b9xV0dO8wzzzzguD0CHBp5RgVp2NpispKQXfQLtUUFrKipDNP3oHHaT0ijGmDaW0wdtoh0lR06Yiu6h_jM5rNx9MKoItspnTMBTguyJ4HYbQr_oRPPRmNH76onoHWYyQ0nprejGrTUiT84vxvIDCQ4wwuaUpolk6876PtiwMyRx81z30fH31NLst7x9u7maX96WmlPGSMU6IbWtLpdWd6VqsWwuaSY0pMRok2ApanktrBeFc1i0TguiO85rICrM9dLH2nS_aHEnnxBEGNY9uhPihAjj1f-Ldi-rDUjVVQ-uVwfG3QQxvC5MmNbqkzTCAN2GRFK1E0wgpG5LRkzWqY0gpGvt7hmC1eo7Kh7JSgmf46G-wX_TnFewTOaWNGA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759956691</pqid></control><display><type>article</type><title>Principles of medical and oncological management of giant masses of the mediastinum: a narrative review</title><source>PubMed Central</source><creator>Conci, Nicole ; Grilli, Giada ; Dall'Olio, Filippo G</creator><creatorcontrib>Conci, Nicole ; Grilli, Giada ; Dall'Olio, Filippo G</creatorcontrib><description>Giant mediastinal tumors are represented by well-defined histological variants originating from different structures and compartments while their clinical presentation may be similar and characterized by the same set of symptoms, the well-known mediastinal syndrome (MS). In 80% of cases the MS is caused by malignant neoplasms, such as lung tumors, in 10-18% of cases by hematological neoplasms and in 2-3% by benign causes. In this review we investigated the medical treatment of main giant mediastinal tumors, focusing our interest on the objective response rate (ORR), as it represents the most suitable parameter to predict the volumetric reduction of the neoplasm and, consequently, the regression of their most severe complication, the MS. We will also cover the supportive and symptomatic treatment of MS. We performed a deep analysis of the recent international literature published on PUBMED, UpToDate and Medline. The literature search was undertaken from origin until November 30th, 2021, and we only considered publications in English. Considering the variety of pathologies that can occur in the mediastinum, a rapid histological characterization of the neoplasm is mandatory. In fact, the treatment of these neoplasms includes different approaches, sometimes used in combination, which include chemotherapy, radiotherapy, and surgery. The vena cava syndrome (VCS), due to its high mortality, is considered an oncological emergency and, therefore, requires effective treatments carried out urgently, evaluated in multidisciplinary meeting. The treatment of MS includes both antiblastic treatments and therapies directed to the symptoms. Among the former, chemotherapy, target therapy, radiation and surgery may be used, according to the etiology of MS. Among the latters, supportive therapies, interventional radiology procedures such as stenting may help manage this syndrome, despite the prognosis is poor in most cases and linked to the histology of the tumor, which therefore represents the most important prognostic factor.</description><identifier>ISSN: 2522-6711</identifier><identifier>EISSN: 2522-6711</identifier><identifier>DOI: 10.21037/med-21-54</identifier><identifier>PMID: 36582971</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Review</subject><ispartof>Mediastinum (Hong Kong, China), 2022, Vol.6, p.35-35</ispartof><rights>2022 Mediastinum. All rights reserved.</rights><rights>2022 Mediastinum. All rights reserved. 2022 Mediastinum.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2234-33411fb8f26fcdedb0cbfac36c021eca6af7ab46afbf514468b3551cd44816703</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792870/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792870/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36582971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conci, Nicole</creatorcontrib><creatorcontrib>Grilli, Giada</creatorcontrib><creatorcontrib>Dall'Olio, Filippo G</creatorcontrib><title>Principles of medical and oncological management of giant masses of the mediastinum: a narrative review</title><title>Mediastinum (Hong Kong, China)</title><addtitle>Mediastinum</addtitle><description>Giant mediastinal tumors are represented by well-defined histological variants originating from different structures and compartments while their clinical presentation may be similar and characterized by the same set of symptoms, the well-known mediastinal syndrome (MS). In 80% of cases the MS is caused by malignant neoplasms, such as lung tumors, in 10-18% of cases by hematological neoplasms and in 2-3% by benign causes. In this review we investigated the medical treatment of main giant mediastinal tumors, focusing our interest on the objective response rate (ORR), as it represents the most suitable parameter to predict the volumetric reduction of the neoplasm and, consequently, the regression of their most severe complication, the MS. We will also cover the supportive and symptomatic treatment of MS. We performed a deep analysis of the recent international literature published on PUBMED, UpToDate and Medline. The literature search was undertaken from origin until November 30th, 2021, and we only considered publications in English. Considering the variety of pathologies that can occur in the mediastinum, a rapid histological characterization of the neoplasm is mandatory. In fact, the treatment of these neoplasms includes different approaches, sometimes used in combination, which include chemotherapy, radiotherapy, and surgery. The vena cava syndrome (VCS), due to its high mortality, is considered an oncological emergency and, therefore, requires effective treatments carried out urgently, evaluated in multidisciplinary meeting. The treatment of MS includes both antiblastic treatments and therapies directed to the symptoms. Among the former, chemotherapy, target therapy, radiation and surgery may be used, according to the etiology of MS. Among the latters, supportive therapies, interventional radiology procedures such as stenting may help manage this syndrome, despite the prognosis is poor in most cases and linked to the histology of the tumor, which therefore represents the most important prognostic factor.</description><subject>Review</subject><issn>2522-6711</issn><issn>2522-6711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LxDAQhoMoKurFHyA9ilDNd1sPgix-gaAHPYdpmtRIm6xJd8V_b9xV0dO8wzzzzguD0CHBp5RgVp2NpispKQXfQLtUUFrKipDNP3oHHaT0ijGmDaW0wdtoh0lR06Yiu6h_jM5rNx9MKoItspnTMBTguyJ4HYbQr_oRPPRmNH76onoHWYyQ0nprejGrTUiT84vxvIDCQ4wwuaUpolk6876PtiwMyRx81z30fH31NLst7x9u7maX96WmlPGSMU6IbWtLpdWd6VqsWwuaSY0pMRok2ApanktrBeFc1i0TguiO85rICrM9dLH2nS_aHEnnxBEGNY9uhPihAjj1f-Ldi-rDUjVVQ-uVwfG3QQxvC5MmNbqkzTCAN2GRFK1E0wgpG5LRkzWqY0gpGvt7hmC1eo7Kh7JSgmf46G-wX_TnFewTOaWNGA</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Conci, Nicole</creator><creator>Grilli, Giada</creator><creator>Dall'Olio, Filippo G</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2022</creationdate><title>Principles of medical and oncological management of giant masses of the mediastinum: a narrative review</title><author>Conci, Nicole ; Grilli, Giada ; Dall'Olio, Filippo G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2234-33411fb8f26fcdedb0cbfac36c021eca6af7ab46afbf514468b3551cd44816703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Conci, Nicole</creatorcontrib><creatorcontrib>Grilli, Giada</creatorcontrib><creatorcontrib>Dall'Olio, Filippo G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Mediastinum (Hong Kong, China)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conci, Nicole</au><au>Grilli, Giada</au><au>Dall'Olio, Filippo G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Principles of medical and oncological management of giant masses of the mediastinum: a narrative review</atitle><jtitle>Mediastinum (Hong Kong, China)</jtitle><addtitle>Mediastinum</addtitle><date>2022</date><risdate>2022</risdate><volume>6</volume><spage>35</spage><epage>35</epage><pages>35-35</pages><issn>2522-6711</issn><eissn>2522-6711</eissn><abstract>Giant mediastinal tumors are represented by well-defined histological variants originating from different structures and compartments while their clinical presentation may be similar and characterized by the same set of symptoms, the well-known mediastinal syndrome (MS). In 80% of cases the MS is caused by malignant neoplasms, such as lung tumors, in 10-18% of cases by hematological neoplasms and in 2-3% by benign causes. In this review we investigated the medical treatment of main giant mediastinal tumors, focusing our interest on the objective response rate (ORR), as it represents the most suitable parameter to predict the volumetric reduction of the neoplasm and, consequently, the regression of their most severe complication, the MS. We will also cover the supportive and symptomatic treatment of MS. We performed a deep analysis of the recent international literature published on PUBMED, UpToDate and Medline. The literature search was undertaken from origin until November 30th, 2021, and we only considered publications in English. Considering the variety of pathologies that can occur in the mediastinum, a rapid histological characterization of the neoplasm is mandatory. In fact, the treatment of these neoplasms includes different approaches, sometimes used in combination, which include chemotherapy, radiotherapy, and surgery. The vena cava syndrome (VCS), due to its high mortality, is considered an oncological emergency and, therefore, requires effective treatments carried out urgently, evaluated in multidisciplinary meeting. The treatment of MS includes both antiblastic treatments and therapies directed to the symptoms. Among the former, chemotherapy, target therapy, radiation and surgery may be used, according to the etiology of MS. Among the latters, supportive therapies, interventional radiology procedures such as stenting may help manage this syndrome, despite the prognosis is poor in most cases and linked to the histology of the tumor, which therefore represents the most important prognostic factor.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>36582971</pmid><doi>10.21037/med-21-54</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2522-6711
ispartof Mediastinum (Hong Kong, China), 2022, Vol.6, p.35-35
issn 2522-6711
2522-6711
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9792870
source PubMed Central
subjects Review
title Principles of medical and oncological management of giant masses of the mediastinum: a narrative review
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T18%3A17%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Principles%20of%20medical%20and%20oncological%20management%20of%20giant%20masses%20of%20the%20mediastinum:%20a%20narrative%20review&rft.jtitle=Mediastinum%20(Hong%20Kong,%20China)&rft.au=Conci,%20Nicole&rft.date=2022&rft.volume=6&rft.spage=35&rft.epage=35&rft.pages=35-35&rft.issn=2522-6711&rft.eissn=2522-6711&rft_id=info:doi/10.21037/med-21-54&rft_dat=%3Cproquest_pubme%3E2759956691%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2759956691&rft_id=info:pmid/36582971&rfr_iscdi=true